Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature

Author(s): Madhavkumar Dilipbhai Trivedi*, Gaurang Dubal and Pratik Ashwinbhai Vora

Volume 17, Issue 2, 2023

Published on: 05 October, 2023

Page: [96 - 109] Pages: 14

DOI: 10.2174/2772270817666230914103435

Price: $65

Abstract

Nintedanib is a competitive inhibitor of non-receptor tyrosine kinase (nRTKs) and receptor tyrosine kinase (RTKs). Nintedanib is a substrate for the P-glycoprotein transporter, which returns ingested substances to the gastrointestinal lumen. At present, Nintedanib is being prescribed for individuals diagnosed with idiopathic pulmonary fibrosis (IPF). This assessment provides a concise overview of the latest patents pertaining to Nintedanib. The patents covered in this analysis are categorized into sections, including patents related to the active ingredient, polymorph, formulation, and treatment method. The purpose of this compilation is to offer researchers convenient access to all the relevant patents in a single resource. Information was collected from diverse web databases, including both paid and free sources. Paid databases, such as Orbit® and SciFinder® were utilized as examples. On the other hand, free databases, such as the European Patent Office's Espacenet®, WIPO Patentscope® the Indian patent database, and Google Patents, were also accessed for data gathering purposes. The orange-book listed patents for Nintedanib are set to expire in July 2029. These patents explore various excipients to address the solubility issue in the long-term storage of the formulation. However, despite these efforts, there is still a need for further research to enhance the properties of the Nintedanib formulation. Extensive research has been conducted on multiple methods for manufacturing Nintedanib and its formulations. This dynamic study has the potential to create opportunities for numerous generic companies to enter the United States market. This, in turn, will improve healthcare accessibility by lowering costs.

« Previous Next »
Graphical Abstract

[1]
Idiopathic pulmonary fibrosis. 2021. Available From: http://en.wikipedia.org/wiki/Idiopathic_pulmonary_fibrosis (Accessed on: December 27 2021).
[2]
Interstitial lung disease. 2021. Available From: http://www.mayoclinic.org/diseases-conditions/interstitial-lung-di sease/symptoms-causes/syc-20353108#:~:text=Interstitial%20 (Accessed on: December 28 2021).
[3]
Ofev fda label 2021. Available From: http://www.tga.gov.au/sites/default/files/auspar-Nintedanib-as-esil ate-210226-pi.pdf (Accessed on December 28, 2021).
[4]
Ofev auspar label. 2021. Available From: http://www.tga.gov.au/sites/default/files/auspar-Nintedanib-as-esil ate-210226.pdf (Accessed on: December 28 2021).
[5]
Summary on product characteristics. 2021. Available From: http://www.ema.europa.eu/en/documents/product-information/ofe v-epar-product-information_en.pdf (Accessed on: December 28 2021).
[6]
Orange book database. 2019. Available From: http://www.accessdata.fda.gov/scripts/cder/ob/_info.cfm?Product_No=001Appl_No=021602Appl_type=N (Accessed on: October 2 2019).
[7]
Gerald Juergen R, Armin H, Rainer W, et al. Substituted indolines which inhibit receptor tyrosine kinases. US Patent 6762180, 1999.
[8]
Joern M, Guenter L, Juergen S, et al. Process for the manufacture of an indolinone derivative. EP Patent 2229359 , 2007.
[9]
XuenongX. Preparation method of Nintedanib.. US Patent 9856215, , 2014.
[10]
Cheng G. One kettle way prepares the synthetic method of Nintedanib. CN Patent 104844499 , 2015.
[11]
Li Y, Hu W, Du H, Wang W, Liu Y. Preparation method of Nintedanib. CN Patent 105461609 , 2015.
[12]
Ludek M. Method for preparing methyl (Z)-3-[[[4-[methyl[2-(4- methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene) oxindole-6-carboxylate US Patent 10125122., 2015.
[13]
Samir N, Sachin S, Pramod P, Premchand P, Shekhar B. Process for the preparation of nintedanib IN Patent 201721031509 , 2017.
[14]
Wu L, Li MZhW, et al. Preparation method of ethanesulfonic acid nintedanib CN Patent 109988094 , 2019.
[15]
Victor P, Sasidaran M, Jeyakanthan J, Uttam K, Tangirala V. An improved process for the preparation of nintedanib esylate IN201741039806 IN Patent 201741039806 , 2019.
[16]
Yang J, Gu Nanping, Guo Ha, et al. Preparation method of highpurity ethanesulfonic acid nintedanib CN Patent 111848490 , 2020.
[17]
Li Zhang, Wang Do, Zhang Xi, Meng Qi, Sheng Li. Method for preparing ethanesulfonic acid nintedanib CN Patent 111848486 , 2020.
[18]
Veera R, AravaSurendra R, GOGI R, Venkateswarlu J. Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof WO Patent 2016178064 , 2015.
[19]
Hubo W, Xueyan Zh, Gu Meng, Min HU, Jiasong Zh, Jiude Sun. Nintedanib diethanesulfonate salt crystal and preparation method and use thereof US Patent 10292965, 2015.
[20]
Ramakoteswara J, Anjaneyaraju I, Aggi R, et al. An amorphous nintedanib esylate and solid dispersion thereof WO Patent 2017077551 , 2015.
[21]
Barbara N, Jacopo B. Stella De, Francesco C. Polymorph of nintedanib WO Patent 2017211777, 2016.
[22]
Ning X. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof. WO Patent 2017218365, 2016.
[23]
Meng Xiaoming. Novel crystal form of nintedanib, manufacturing method thereof, and application of same WO Patent 2017198202 , 2016.
[24]
Xi Zhang, Jiang Yu, Song Zh, Bao Ji. New medicine crystal form of nintedanib ethanesulfonate hydrate CN Patent 106432042 , 2016.
[25]
Xi Ning, Mingming S. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof. EP Patent 3373934 , 2015.
[26]
Xi Ning, Mingming S. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof. US Patent 9920033 , 2015.
[27]
Liu Fei, Cuixia Zh, Weiming Ji, Chin yu L, Tan N, Haolong Zh. Crystalline forms of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-meth ylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl- methylene]- 6-methoxycarbonyl-2-indolinone US Patent 10961203 , 2017.
[28]
Ji Ma, Ren Ba, Li Tao, Li Hu. Preparation of new crystal form I of nintedanib ethanesulfonate CN Patent 113024439, , 2021.
[29]
winner P, Werner R, Guenter L, Mihaela P, Jaroslaw M. Salts and crystalline salt forms of an 2-indolinone derivative WO Patent 2007/141283 , 2006.
[30]
Eszter T, Marcela T, Ondrej D, Tomas G. Crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]ami no} phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-in dole-6-carboxylate salts and methods of preparation thereof. US Patent 10532981 , 2016.
[31]
Gerald J, Armin H, Rainer W, et al. Use of Lck inhibitors for treatment of immunologic diseases US Patent 7989474, 2022.
[32]
Frank H, Flavio S, Anke B, Jacobus CA. Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis. US Patent 7846936 , 2003.
[33]
Gerd M, Martin S, Anke B. Combinations for the treatment of diseases involving cell proliferation. US Patent 8143247 , 2004.
[34]
Wolfgang S, Norbert K, Norbert S, et al. Treatment of cancer WO Patent 2007057397, 2005.
[35]
Flavio S, Andree A, Gerd S, Jacobus CA, Anke B. Combination treatment of cancer comprising egfr/her2 inhibitors EP Patent 1948180, 2005.
[36]
Tokuzo A, Kanae K, Kazuhiko N, Kazuto N. Method or system using biomarkers for the monitoring of a treatment. EP Patent 2406628 , 2009.
[37]
Sharon M, Prafulla C, Robert C. Wild. Mtor inhibitor and angiogenesis inhibitor combination therapy. WO Patent 2011014726, 2009.
[38]
Birgit G, Rolf K. Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment. EP Patent 2994125 , 2013.
[39]
Wang X, Han L. Ethanesulfonic acid nintedanib preparation and application thereof. CN Patent 105902507 , 2016.
[40]
Susanne S. Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone. WO Patent 2017203027 , 2016.
[41]
Susanne S, Cludia D. Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone. WO Patent 2017207643 , 2016.
[42]
Guo S, Zhang J. The pharmaceutical composition and its application of prevention or treatment fibrotic disease. CN Patent 107019697 , 2016.
[43]
Hidetoshi H, Kazuhiko N, Kazuto N, et al. Method using a ret fusion gene as a biomarker to select non-small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment. WO Patent 2017097697 , 2015.
[44]
Mu, Guo S, Zhang J. A kind of medicine for preventing or treating CNV to be formed. CN Patent 106902117 , 2015.
[45]
Ni Jinsong, Rong Y. Compositions and methods of using nintedanib for improving glaucoma surgery success. US Patent 10335408 , 2016.
[46]
Lu Y, Wang J, Du G, et al. Application of nintedanib in preparing medicament for preventing and treating liver fibrosis and hepatocirrhosis. CN Patent 106692150 , 2016.
[47]
De Mi, Hu Qi, Ze L, Lu S. Nintedanib is used to treat the purposes in the external preparation medicine of psoriasis. CN Patent 107028949, 2017.
[48]
Guo S, Zhang J. Nintedanib prevents the purposes of eye disease. CN Patent 108295072 , 2015.
[49]
Stefan L, Jorge W. Nintedanib for use in methods for the treatment of muscular dystrophy. WO Patent 2018177893 , 2017.
[50]
Xu Y, Huang X, Jinsong Huang F. A kind of Nintedanib inclusion compound, preparation and preparation method thereof. CN Patent 108144069 , 2016.
[51]
Stefan W, Va W, Franziska H. Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol. EP Patent 3551187 , 2016.
[52]
Yao Z, Guo S, Zhang J. A kind of drug prevented or treat kidney fibrosis disease. CN Patent 108066343, 2016.
[53]
Shuhua G, Jiewen Z, Xinting Y, Zongren Y. Composition for treating ocular diseases and methods of usage and making. US Patent 10772885 , 2016.
[54]
Zhang B, Hu J. A kind of Neulized inhalation Nintedanib freezedried lipidosome preparation and preparation method thereof. CN Patent 109758437, 2017.
[55]
Franziska Elena H, Peter N, Stefan L, Michael W. New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild). EP Patent 3700529 , 2017.
[56]
Zhou H, Li H, Wei Y. Application of nintedanib in preparation of medicine for treating inflammatory bowel disease. CN Patent 111789842 , 2020.
[57]
Tian Fang G, Zhang C. Anti-pulmonary fibrosis composition with improved dissolution property. CN Patent 111973596 , 2020.
[58]
Benjamin S, Patrick B, Claudia D. Use of biomarkers in the treatment of fibrotic conditions. WO Patent 2021198253 , 2020.
[59]
Fu Y, Gong Tao L, Xiao Cao J, Zhao He Z, Xiaowu Li J. New medicinal application of nintedanib, derivatives or medicinal salts thereof. CN Patent 112972474 , 2021.
[60]
Chang Hui Sun W. Compounds for treatment of schizophrenia and their use. CN Patent 103800335 , 2012.
[61]
Tan N, Chin-yu L. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof. US Patent 10154994 , 2015.
[62]
Wang X, Han L. Ethanesulfonic acid nintedanib dispersible tablet and preparation method thereof. CN Patent 105963268 , 2016.
[63]
Xu Y, Feng Wenxiao H, Taofeng Liu H, Lu S. Nintedanib selfmicroemulsion preparation, soft capsule prepared from same and preparation method of soft capsule. CN Patent 107184549 , 2017.
[64]
Miao D, Hu Q, Wang H, Lu Shuai A, Yu Zeng L. Ethanesulfonic acid Nintedanib soft capsule and preparation method thereof. CN Patent 108078952 , 2018.
[65]
Zeng L, Xiaosong C, Xianliang H, et al. Methods for preparing Nintedanib and intermediates thereof. US Patent 10836751 , 2016.
[66]
Nilesh Bhagwat T, Pradosh Ranjan S, Sunil Shantwan B, Venkataramana N. Pharmaceutical composition of nintedanib esylate. US Patent 20210137917 , 2018.
[67]
Bhushan J, Harshal J, Amol K, Shirish K, Rajamannar T. Oral suspension of nintedanib esylate. WO Patent 2019106692 , 2017.
[68]
He H. High-bioavailability nintedanib nano lipid carrier and preparation method thereof. CN Patent 110623927 , 2018.
[69]
Naoto U, Naoto Uemura N, Otani N, Otani K, Wakuta Koichi W. Medicine for prevention and treatment of chronic fatty disease. JP Patent 2019182764 , 2018.
[70]
Mark William S, Stephen P. Specially formulated compositions of inhaled nintedanib and nintedanib salts. US Patent 11123290 , 2018.
[71]
Gong Y, Chen L, Wang Z, Wang W. Eye temperature-sensitive gel and preparation method thereof. CN Patent 110787127 , 2019.
[72]
Geena Vinod M, Preeti Prashant R, aibhav Panditrao D, Dipak Narayan D. Pharmaceutical formulation. EP Patent 3860569, 2018.
[73]
Liu Hongfei W, Fen Zou Y, Zhang Q. Quantum dot and Nintedanib composite microsphere and preparation method thereof. CN Patent 113133972 , 2021.
[74]
Tian Fang G, Xing D. Nintedanib-glycyrrhetinic acid compound preparation, medicine compound preparation and application of medicine compound preparation in preparation of medicine for treating pulmonary fibrosis. CN Patent 113116904 , 2021.
[75]
Li Yuting L, Baoming Y, Qingmin Xu X, Zhang M. Nintedanib medicinal preparation with improved dissolution rate and stability, preparation method and application thereof. CN Patent 112386580, 2019.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy